74 / 89
74
calcinosis cutis in CREST syndrome. Arch
Dermatol 2009;145:212-3.
55.
Bottomley WW, Goodfield MJ, Sheehan-Dare
RA. Digital calcification in systemic sclerosis:
effective
treatment
with
good
tissue
preservation using the carbon dioxide laser. Br J
Dermatol 1996;135:302-4.
56.
Sparsa A, Lesaux N, Kessler E, Bonnetblanc JM,
Blaise S, Lebrun-Ly V, et al. Treatment of
cutaneous calcinosis in CREST syndrome by
extracorporeal shock wave lithotripsy. J Am
Acad Dermatol 2005;53(5 Suppl 1):S263-5.
57.
Thompson AE, Shea B, Welch V, Fenlon D, Pope
JE. Calcium-channel blockers for Raynaud's
phenomenon in systemic sclerosis. Arthritis
Rheum 2001;44:1841-7.
58.
Kahan A, Amor B, Menkès CJ, Weber S, Guérin
F, Degeorges M. Nicardipine in the treatment of
Raynaud's phenomenon: a randomized double-
blind trial. Angiology 1987;38:333-7.
59.
Kahan A, Amor B, Menkes CJ. A randomised
double-blind trial of diltiazem in the treatment
of Raynaud's phenomenon. Ann Rheum Dis
1985;44:30-3.
60.
Hummers LK, Wigley FM. Management of
Raynaud’s phenomenon and digital ischemic
lesions in scleroderma. Rheum Dis Clin North
Am 2003;29:293-313
61.
Wigley FM, Wise RA, Seibold JR, McCloskey
DA, Kujala G, Medsger TA Jr, et al. Intravenous
iloprost infusion in patients with Raynaud